Latest Breaking News On - Esther latres - Page 1 : comparemela.com

JDRF-Authored Paper Shows Pathway to Accelerate Disease-Modifying Therapies for People with Type 1 Diabetes

/PRNewswire/ A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of.

JDRF-Authored Paper Shows Pathway To Accelerate Disease-Modifying Therapies For People With Type 1 Diabetes

C-peptide, a biomarker that indicates insulin production, is a validated surrogate endpoint in type 1 diabetes clinical trials NEW YO

Humacyte (HUMA) and JDRF Collaborate to Develop Insulin-Producing Biovascular Pancreas to Treat Type 1 Diabetes

Humacyte, JDRF Collaborating to Develop Insulin-Producing Biovascular Pancreas to Treat Type 1 Diabetes

NEW YORK, N.Y. and DURHAM, N.C., April 27, 2023 Humacyte, Inc. , a biotechnology company pioneering the development and manufacturing of off-the-shelf, universally implantable bioengineered. | April 27, 2023

Scientists Use 'Gentler' Cell Transplants to Reverse Diabetes in Mice

TUESDAY, Nov. 8, 2022 (HealthDay News) Scientists have used a transplant procedure to apparently cure diabetes in lab mice, without the need for immune-suppressing drugs afterward.